Morgan Stanley Kymera Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 239,763 shares of KYMR stock, worth $7.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

239,763

Previous 488,077 50.88%

Holding current value

$7.1 Million

Previous $23.1 Million 58.25%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$39.06 - $51.84 $9.7 Million - $12.9 Million	-248,314 Reduced 50.88%	239,763 $9.65 Million
Q3 2024 Nov 14, 2024	SELL	$30.16 - $52.4 $4.33 Million - $7.53 Million	-143,661 Reduced 22.74%	488,077 $23.1 Million
Q2 2024 Oct 17, 2024	BUY	$29.85 - $39.42 $2.53 Million - $3.33 Million	84,598 Added 15.46%	631,738 $18.9 Million
Q2 2024 Aug 14, 2024	BUY	$29.85 - $39.42 $2.53 Million - $3.33 Million	84,598 Added 15.46%	631,738 $18.9 Million
Q1 2024 Oct 17, 2024	SELL	$22.9 - $43.57 $1.94 Million - $3.69 Million	-84,598 Reduced 13.39%	547,140 $22 Million
Q1 2024 Aug 16, 2024	BUY	$22.9 - $43.57 $2.42 Million - $4.61 Million	105,862 Added 23.99%	547,140 $22 Million
Q1 2024 May 15, 2024	BUY	$22.9 - $43.57 $2.42 Million - $4.61 Million	105,862 Added 23.99%	547,140 $22 Million
Q4 2023 Aug 16, 2024	SELL	$10.97 - $26.84 $2.09 Million - $5.11 Million	-190,460 Reduced 30.15%	441,278 $11.2 Million
Q4 2023 Feb 13, 2024	BUY	$10.97 - $26.84 $1.12 Million - $2.74 Million	101,950 Added 30.04%	441,278 $11.2 Million
Q3 2023 Nov 15, 2023	SELL	$13.9 - $23.88 $925,420 - $1.59 Million	-66,577 Reduced 16.4%	339,328 $4.72 Million
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $1.78 Million - $2.78 Million	79,583 Added 24.39%	405,905 $9.33 Million
Q1 2023 May 15, 2023	BUY	$24.84 - $38.75 $2.2 Million - $3.43 Million	88,520 Added 37.22%	326,322 $9.67 Million
Q4 2022 Feb 14, 2023	BUY	$19.57 - $30.92 $1.27 Million - $2.01 Million	65,052 Added 37.66%	237,802 $5.94 Million
Q3 2022 Nov 14, 2022	SELL	$20.91 - $34.27 $3.37 Million - $5.53 Million	-161,399 Reduced 48.3%	172,750 $3.76 Million
Q2 2022 Oct 27, 2022	BUY	$14.13 - $42.55 $2.1 Million - $6.33 Million	148,666 Added 80.15%	334,149 $6.58 Million
Q2 2022 Aug 15, 2022	BUY	$14.13 - $42.55 $2.1 Million - $6.33 Million	148,666 Added 80.15%	334,149 $6.58 Million
Q1 2022 Oct 27, 2022	SELL	$35.3 - $64.68 $5.25 Million - $9.62 Million	-148,666 Reduced 44.49%	185,483 $7.85 Million
Q1 2022 May 13, 2022	BUY	$35.3 - $64.68 $3.65 Million - $6.69 Million	103,358 Added 125.85%	185,483 $7.85 Million
Q4 2021 Feb 14, 2022	SELL	$49.91 - $65.56 $271,310 - $356,384	-5,436 Reduced 6.21%	82,125 $5.21 Million
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $4.19 Million - $5.84 Million	87,561 New	87,561 $5.14 Million

Others Institutions Holding KYMR

# of Institutions

185

Shares Held

60.3M

Call Options Held

49.6K

Put Options Held

17K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.62B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account